EXHIBIT 10.214 FIFTEENTH ADDENDUM TO AMENDED REGISTRATION RIGHTS AGREEMENT This Fifteenth Addendum ("Addendum") to the Amended Registration Rights Agreement dated June 24, 1994, as amended through the date hereof ("Registration Rights Agreement") among Ligand Pharmaceuticals Incorporated (the "Company") and the persons and entities listed on Exhibit A hereto (collectively, the "X-Ceptor Investors and Founders") is effective as of October 6, 1999. RECITALS A. The Company has issued warrants to purchase an aggregate of 950,000 shares of the Company's Common Stock with an exercise price equal to $10.00 per share (collectively, the "X-Ceptor Warrants") to the X-Ceptor Investors and Founders. B. This Addendum serves to include any shares of the Company's Common Stock issuable upon the exercise of the X-Ceptor Warrants within the definition of "Registrable Securities" under the Registration Rights Agreement and to provide that Schedule A to the Registration Rights Agreement shall be further updated to include any such shares issued upon the exercise of the X-Ceptor Warrants, all pursuant to Section 2.6(a) of the Registration Rights Agreement. NOW, THEREFORE, in consideration of the mutual promises and covenants set forth in the Registration Rights Agreement, the parties agree as follows: 1. Section 1.1, paragraph (f) of the Registration Rights Agreement is hereby restated in its entirety as follows: "(f) The term "Registrable Securities" means (i) the Common Stock issuable or issued upon exercise of those warrants issued to certain Existing Investors and pursuant to which such Existing Investors were previously granted registration rights by the Company, (ii) the shares of Common Stock (or the shares of such other class of stock into which the Common Stock is converted) issuable upon conversion of those certain Unsecured Convertible Promissory Notes issued to American Home Products Corporation pursuant to the Stock and Note Purchase Agreement dated September 2, 1994, (iii) the 35,957 shares of Common Stock issuable or issued upon exercise of the Warrant issued to Genentech, Inc. in connection with the merger of L.G. Acquisition Corp., a wholly-owned subsidiary of the Company, with and into Glycomed Incorporated, which shares are reflected on Schedule A attached to the Fourth Addendum to this Agreement, (iv) the 164,474 shares of Common Stock (or that number of shares of such other class of stock into which the Common Stock is converted) issued to S.R. One Limited pursuant to a Stock and Note Purchase Agreement dated February 3, 1995 (the "Stock and Note Purchase Agreement"), which shares are reflected on Schedule A attached to the Eighth Addendum to this Agreement, and the shares of Common Stock (or the shares of such other class of stock into which the Common Stock is converted) issuable upon conversion of those certain Unsecured Convertible Promissory Notes dated October 30, 1997 (the "S.R. One Notes") issued pursuant to the Stock and Note Purchase Agreement (and upon such conversion of the S.R. One Notes, Schedule A shall be updated to include such shares), (v) the 274,423 shares of Common Stock (or that number of shares of such other class of stock into which the Common Stock is converted) issued to SmithKline Beecham plc pursuant to a Stock Purchase Agreement dated April 24, 1998 (the "SmithKline Stock Purchase Agreement"), which shares are reflected on Schedule A attached to the Ninth Addendum to this Agreement, and the shares of Common Stock (or the shares of such other class of stock into which the Common Stock is converted) issuable upon conversion of that certain Warrant (the "Warrant") issued pursuant to the SmithKline Stock Purchase Agreement (and upon such conversion of the Warrant, Schedule A shall be updated to include such shares), (vi) the 1,278,970 shares of Common Stock (or that number of shares of such other class of stock into which the Common Stock is converted) issued to Elan International Services, Ltd. pursuant to the Stock Purchase Agreement dated September 30, 1998, which shares are reflected on Schedule A attached to the Tenth Addendum to this Agreement, (vii) the 437,768 shares of Common Stock (or that number of shares of such other class of stock into which the Common Stock is converted) issued to Elan International Services, Ltd. pursuant to the Securities Purchase Agreement, dated November 6, 1998 (the "Elan Securities Purchase Agreement"), which shares are reflected on Schedule A attached to the Eleventh Addendum to this Agreement, (viii) the shares of Common Stock (or the shares of such other class of stock into which the Common Stock is converted) issuable upon conversion of the Zero Coupon Convertible Senior Notes due 2008 (the "Elan Notes") issued pursuant to the Elan Securities Purchase Agreement (and upon such conversion of the Elan Notes, Schedule A shall be updated to include such shares), (viii) the 429,185 shares of Common Stock (or the shares of such other class of stock into which the Common Stock is converted) issued to Elan Corporation, plc pursuant to the Development, License and Supply Agreement dated November 9, 1998 (the "Elan License Agreement"), which shares are reflected on Schedule A attached to the Eleventh Addendum to this Agreement, (ix) the shares of Common Stock that may be issued to Elan Corporation, plc pursuant to the Elan License Agreement (and upon each such issuance, Schedule A shall be updated to include such shares), (x) the shares of Common Stock (or the shares of such other class of stock into which the Common Stock is converted) issuable to Elan International Services, Ltd. upon exercise of that certain Warrant (the "EIS Warrant") dated August 4, 1999 (and upon such exercise of the EIS Warrant, Schedule A shall be updated to include such shares), (xi) the 289,750 shares of Common Stock (or the shares of such other class of stock into which the Common Stock is converted) issued to Warner Lambert Company pursuant to the Purchase Agreement dated September 1, 1999, which shares are reflected on Schedule A attached to the Thirteenth Addendum to this Agreement, (xii) the 52,742 shares of Common Stock (or the shares of such other class of stock into which the Common Stock is converted) issued to EIS pursuant to the Stock Purchase Agreement dated September 30, 1999, which shares are reflected on Schedule A attached to the Fourteenth Addendum to this Agreement, (xiii) the shares of Common Stock (or 2 the shares of such other class of stock into which the Common Stock is converted) issuable upon exercise of those certain Series X Warrants dated [October 6, 1999] (the "X-Ceptor Warrants") (and upon any such exercise of the X-Ceptor Warrants, Schedule A shall be updated to include such shares), and (xiv) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of the shares referenced in (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), (ix), (x), (xi), (xii) and (xiii) above, excluding in all cases, however, any Registrable Securities sold by a person in a transaction in which rights under this Agreement are not assigned." 2. Schedule A of the Registration Rights Agreement is hereby restated in its entirety as attached to this Addendum. 3. This Addendum may be executed in one or more counterparts. 4. This Addendum shall be binding upon the Company, each of the X-Ceptor Investors and Founders, each holder of Registrable Securities and each future holder of Registrable Securities pursuant to Section 2.6(a) of the Registration Rights Agreement. [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 3 IN WITNESS WHEREOF, the parties have executed this Addendum as of the date first above written. LIGAND PHARMACEUTICALS INCORPORATED By: /s/William L. Respess Its: Senior Vice President General Counsel, Government Affairs X-CEPTOR INVESTORS AND FOUNDERS: Domain Partners IV, L.P. By: One Palmer Square Associates IV, L.L.C., General Partner By: /s/Kathleen Schoemaker Its: Managing Member DP IV Associates, L.P. By: One Palmer Square Associates IV, L.L.C., General Partner By: /s/Kathleen Schoemaker Its: Managing Member [SIGNATURE PAGE TO FIFTEENTH ADDENDUM TO AMENDED REGISTRATION RIGHTS AGREEMENT] FARALLON CAPITAL PARTNERS, L.P. FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P. FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P. FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P. RR CAPITAL PARTNERS, L.P. By: Farallon Partners, L.L.C., its General Partner By: /s/David Cohen Its: TechAMP International, L.P. By: AMP&A Management, LLC, General Partner By: /s/ A.M. Papas Its: Manager /s/ Kevin Kinsella - ---------------------- Kevin Kinsella /s/Ronald Evans - ---------------------- Ronald Evans /s/Bert O'Malley - ---------------------- Bert O'Malley /s/David Mangelsdorf - ---------------------- David Mangelsdorf [SIGNATURE PAGE TO FIFTEENTH ADDENDUM TO AMENDED REGISTRATION RIGHTS AGREEMENT] 5 /s/Richard Heyman - ---------------------- Richard Heyman /s/Robert Giargiari - ---------------------- Robert Giargiari /s/Ming Wei Wang - ---------------------- Ming Wei Wang GIMV N.V. By: /s/ illegible /s/ illegible - ---------------------- ---------------------- Its: Vice President Vice President Sofinov Societe Financiere D'Innovation, Inc. By: /s/Jean-Chirtophe Denondin - ------------------------------------- Its: Vice President By: /s/Ginette Depelteau - ------------------------------------- Its: Secretary [SIGNATURE PAGE TO FIFTEENTH ADDENDUM TO AMENDED REGISTRATION RIGHTS AGREEMENT] 6 SCHEDULE A to Fifteenth Addendum to Amended Registration Rights Agreement
- --------------------------------------------------------- --------------------- Shares Name Issued - --------------------------------------------------------- --------------------- American Home Products Corporation 374,626 American Home Products Corporation 374,626 American Home Products Corporation 249,749 American Home Products Corporation 124,875 Aspen Venture Partners, L.P. 2,659 Domain Partners IV, L.P. _______ DP IV Associates, L.P. _______ Elan Corporation, plc 429,185 Elan International Services, Ltd. 1,769,480 Enterprise Partners 3,745 Ronald Evans _______ Farallon Capital Partners, L.P. _______ Farallon Capital Institutional Partners, L.P. _______ Farallon Capital Institutional Partners II, L.P. _______ Farallon Capital Institutional Partners III, L.P. _______ GIMV N.V. _______ Genentech, Inc. 35,957 Robert Giargiari _______ Richard Heyman _______ Kevin Kinsella _______ A-1 Kleiner Perkins Caufield & Byers 7,688 ML Venture Partners II, L.P. 2,417 David Mangelsdorf _______ Bert O'Malley _______ RR Capital Partners, L.P. _______ S.R. One, Limited 164,474 SmithKline Beecham 274,423 Sofinov Societe Financiere D'Innovation _______ TechAMP International, L.P. _______ Venrock Associates 3,441 Venrock Associates II, L.P. 1,540 Ming Wei Wang _______ Warner Lambert Company 289,750 Windsor Venture Lease Partners Ltd., Inc. 283 Total: 4,108,918 - --------------------------------------------------------- --------------------- 2